文献速递消化、代谢与肾脏急症

电子烟与伐尼克兰用于成人戒烟:一项随机临床试验

Electronic Cigarettes vs Varenicline for Smoking Cessation in Adults: A Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2024-01-01
一句话结论在芬兰单中心随机试验中,含尼古丁电子烟与伐尼克兰26周戒烟率均约40%以上,二者无显著差异,均显著优于安慰剂。

这项在芬兰北部开展的单中心随机安慰剂对照试验,纳入458名每日吸烟且自愿戒烟的25至75岁成人,随机分为含尼古丁电子烟组、伐尼克兰组和安慰剂组,干预12周,随访52周。主要终点为第26周时经呼出气一氧化碳确认的自报7天传统香烟戒断率,电子烟组为40.4%,伐尼克兰组为43.8%,安慰剂组为19.7%(P < .001)。两两比较显示,安慰剂与电子烟组风险差为20.7%(95% CI 10.4-30.4,P < .001),与伐尼克兰组风险差为24.1%(95% CI 13.7-33.7,P < .001);电子烟与伐尼克兰之间风险差为3.4%(95% CI -7.6至14.3,P = .56),差异无统计学意义。未报告严重不良事件。作者认为,伐尼克兰和含尼古丁电子烟均有助于戒烟长达6个月。

要点

  • 第26周经呼出气一氧化碳确认的7天戒断率:电子烟组40.4%(61/152)、伐尼克兰组43.8%(67/153)、安慰剂组19.7%(30/153),整体P < .001。
  • 电子烟与伐尼克兰比较:风险差3.4%(95% CI -7.6至14.3,P = .56),差异无统计学意义。
  • 安慰剂与电子烟比较:风险差20.7%(95% CI 10.4-30.4,P < .001);安慰剂与伐尼克兰比较:风险差24.1%(95% CI 13.7-33.7,P < .001)。
  • 未报告严重不良事件。
  • 作者认为,伐尼克兰和含尼古丁电子烟均能帮助个体戒断传统香烟长达6个月。

适用人群与场景

  • 25至75岁每日吸烟且自愿戒烟的成人,2018年8月1日至2020年2月20日通过当地媒体招募自芬兰北部。
  • 研究纳入458名合格参与者(257名女性[56%];201名男性[44%];平均[SD]年龄51[11.6]岁),共招募561名。
  • 干预阶段12周,随访52周。

处置流程与药物剂量

  • 参与者按区组随机分为三组:含尼古丁电子烟(18 mg/mL)联合安慰剂片剂;伐尼克兰按标准剂量联合不含尼古丁电子烟;安慰剂片剂联合不含尼古丁电子烟。
  • 所有组均联合动机性访谈,干预阶段持续12周。
  • 主要终点为第26周时自报7天传统香烟戒断,并经呼出气一氧化碳水平确认;分析遵循意向性治疗原则。

研究设计与关键结果

  • 随机安慰剂对照单中心试验,458名参与者随机分组,主要终点第26周经呼出气一氧化碳确认的7天戒断率:电子烟组40.4%(61/152)、伐尼克兰组43.8%(67/153)、安慰剂组19.7%(30/153),P < .001。
  • 两两比较:安慰剂与电子烟风险差20.7%(95% CI 10.4-30.4,P < .001);安慰剂与伐尼克兰风险差24.1%(95% CI 13.7-33.7,P < .001);电子烟与伐尼克兰风险差3.4%(95% CI -7.6至14.3,P = .56)。
  • 未报告严重不良事件。

证据类型、等级与局限

  • 证据类型:随机安慰剂对照临床试验。
  • 试验注册号:ClinicalTrials.gov Identifier: NCT03235505。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,伐尼克兰和含尼古丁电子烟均能帮助个体戒断传统香烟长达6个月。
  • 原文未据此给出其他推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Little is known about the relative effectiveness of nicotine-containing electronic cigarettes (ECs) compared with varenicline as smoking cessation aids.

OBJECTIVE: To determine the relative effectiveness of ECs in smoking cessation.

DESIGN, SETTING, AND PARTICIPANTS: This randomized placebo-controlled single-center trial was conducted in northern Finland. Participants aged 25 to 75 years who smoked daily and had volunteered to quit smoking were recruited from August 1, 2018, to February 20, 2020, via local media. The trial included 52 weeks of follow-up. All data analyses were conducted from September 1, 2022, to January 15, 2024. The participants, study nurses, and researchers were masked to group assignment.

INTERVENTION: The participants were assigned by block randomization to receive 18 mg/mL of nicotine-containing ECs together with placebo tablets, varenicline with standard dosing together with nicotine-free ECs, or placebo tablets together with nicotine-free ECs, all combined with a motivational interview, with the intervention phase lasting for 12 weeks.

MAIN OUTCOME AND MEASURE: The primary outcome was self-reported 7-day conventional cigarette smoking abstinence as confirmed by the exhaled carbon monoxide level on week 26. The analysis followed the intent-to-treat principle.

RESULTS: Of the 561 recruited participants, 458 (81.6%) eligible participants (257 women [56%]; 201 men [44%]; mean [SD] age, 51 [11.6] years) were randomized. The primary outcome occurred in 61 of 152 participants (40.4%) in the EC group, 67 of 153 (43.8%) in the varenicline group, and 30 of 153 (19.7%) in the placebo group (P < .001). In the pairwise comparison, placebo differed statistically significantly from ECs (risk difference [RD], 20.7%; 95% CI, 10.4-30.4; P < .001) and varenicline (RD, 24.1%; 95% CI, 13.7-33.7; P < .001), but the difference was statistically insignificant between ECs and varenicline (RD, 3.4%; 95% CI, -7.6 to 14.3; P = .56). No serious adverse events were reported.

CONCLUSIONS: This randomized clinical trial found that varenicline and nicotine-containing ECs were both effective in helping individuals in quitting smoking conventional cigarettes for up to 6 months.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03235505.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Tuisku A, Rahkola M, Nieminen P, et al. Electronic Cigarettes vs Varenicline for Smoking Cessation in Adults: A Randomized Clinical Trial. JAMA Intern Med. 2024. PMID: 38884987. doi:10.1001/jamainternmed.2024.1822

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。